系统性硬化症晚期皮肤纤维化:一项来自EUSTAR队列的研究
基于EUSTAR数据库1043例系统性硬化症患者,约五分之一(208/1043,19.9%)出现改良Rodnan皮肤评分(mRSS)加重;基线mRSS较低和局限型皮肤型患者更易发生晚期皮肤纤维化,抗Scl-70与从局限型进展为弥漫型相关,抗着丝点抗体具有保护作用。
要点
- 全队列中208/1043例(19.9%)出现mRSS加重,基线为局限型或弥漫型者中193/887例(21.8%)出现加重。
- 基线mRSS较低和局限型皮肤型患者更易发生晚期皮肤纤维化。
- 抗Scl-70与从基线局限型进展为弥漫型相关,抗着丝点抗体具有保护作用。
核心结论
- 晚期皮肤纤维化在系统性硬化症中并不少见,存在与临床实践和试验设计相关的不同模式。
- 晚期皮肤纤维化是被忽视的系统性硬化症表现,需进一步研究以确定临床结局和最佳治疗策略。
研究设计与样本
- 研究基于EUSTAR数据库,设计并检验了晚期皮肤纤维化的三种概念情景,包括新发皮肤加重以及5年窗口内加重后未能改善。
- 皮肤加重定义为改良Rodnan皮肤评分(mRSS)变化≥5单位或≥25%。
- 采用严格纳入标准(包括完整mRSS),从EUSTAR数据库19115例中识别1043例进行分析,并进一步限制在基线为局限型或弥漫型皮肤型的887/1043例中分析。
主要发现
- 全队列中208/1043例(19.9%)经历mRSS加重,基线为局限型或弥漫型者中193/887例(21.8%)经历加重。
- 加重主要归因于5年窗口后的新发皮肤加重或5年窗口内加重后未能改善。
- 基线mRSS较低和局限型皮肤型患者更可能发生晚期皮肤纤维化。
- 抗Scl-70与从基线局限型皮肤型进展为弥漫型皮肤型相关,抗着丝点抗体具有保护作用。
关键数值与推荐
- 皮肤加重定义为mRSS变化≥5单位或≥25%。
- 晚期皮肤纤维化定义为首次非雷诺现象特征后>5年出现的皮肤纤维化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The early trajectory of skin fibrosis provides insights into the disease course of systemic sclerosis (SSc) including mortality; however, little is known about late skin fibrosis. The aims of our study were to ascertain the prevalence and characteristics of late skin fibrosis in SSc. METHODS: We developed and tested three conceptual scenarios of late (>5 years after first non-RP feature) skin fibrosis including new worsening of skin disease, and failure to improve after worsening within 5-year window. We defined skin worsening as change in modified Rodnan skin score (mRSS) ≥5 units or ≥25%. Using strict inclusion criteria including complete mRSS, we identified 1,043 (out of 19 115) patients within the EUSTAR database for our analysis. We further restricted analysis within 887 (out of 1043) patients who had lcSSc or dcSSc at baseline. RESULTS: One-fifth of patients among the whole cohort (n = 208/1043, 19.9%) experienced mRSS worsening, including in patients with lcSSc or dcSSc at baseline (n = 193/887, 21.8%). This was largely due to new skin worsening after the 5-year window or failure to improve with worsening within the 5-year window. Patients with lower baseline mRSS and lcSSc were more likely to develop late skin fibrosis. Anti-Scl-70 was associated with progression from baseline lcSSc to dcSSc, and anticentromere was protective. CONCLUSIONS: Late skin fibrosis is not uncommon in SSc. We have identified different patterns relevant to clinical practice and trial design. Late skin fibrosis is a neglected manifestation of SSc and warrants further investigation including to determine clinical outcomes and optimal therapeutic strategy.
引用
- Hughes M, Huang S, Alegre-Sancho JJ, et al. Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology (Oxford). 2023. PMID: 35731139. doi:10.1093/rheumatology/keac363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。